Researcher
Marine Jean Christophe
- Disciplines (Flanders Institute for Biotechnology):Analysis of next-generation sequence data, Cell death, Cancer biology
- Disciplines (KU Leuven):Morphological sciences, Oncology
- See also: Chris Marine (KU Leuven)
Affiliations
- Laboratory for Molecular Cancer Biology (VIB-KU Leuven) (Division)
Responsible
From1 Jan 2017 → Today - VIB-KU Leuven Center for Cancer Biology (Research Center)
Responsible
From1 Jan 2017 → Today - Marine Lab (Research group)
Responsible
From1 Jan 2017 → Today - Laboratory for Molecular Cancer Biology (VIB-KU Leuven) (Division)
Member
From1 Oct 2013 → Today - Department of Human Genetics (Department)
Member
From1 Oct 2009 → 31 Dec 2016
Projects
1 - 10 of 10
- VIB Grant for Marine Lab_Period:2022-01-01-2026-12-31From1 Jan 2022 → TodayFunding: FRI - Project driven research
- Eradicating the minimal residual disease in melanomaFrom1 Jan 2022 → TodayFunding: Other international institutions, not mentioned elsewhere
- International PhD Programme for Medical DoctorsFrom1 Jan 2022 → TodayFunding: Other EU initiatives out of framework
- 4D TUMORMAPFrom1 Jul 2021 → 30 Jun 2022Funding: Other international institutions, not mentioned elsewhere
- Understanding resistance to immune checkpoint inhibitors by mapping the tumor-host ecosystem at single-cell resolution — cellsIMPACT - marie curie individual fellowship Joanna PozniakFrom1 May 2020 → 30 Apr 2022Funding: HORIZON.1.2 - Marie Skłodowska-Curie-actions (MSCA)
- 'Exploring the non-genetic (i.e. ePIgenetic) mechanisms that contribute to therapy Escape in melanoma — EscaPI - Marie curie individual fellowship Aurélie BoussardFrom1 May 2020 → 30 Apr 2022Funding: HORIZON.1.2 - Marie Skłodowska-Curie-actions (MSCA)
- Melanoma Research alliance awardFrom1 Jun 2019 → 31 May 2022Funding: Other international institutions, not mentioned elsewhere
- Intra-tumoral heterogeneity in NRAS-driven metastatic melanoma — INHuMAN’ (marie curie individual fellowship voor Karras Panagiotis)From1 Apr 2019 → 31 Mar 2021Funding: HORIZON.1.2 - Marie Skłodowska-Curie-actions (MSCA)
- Revolutionizing Healthcare by Tracking and Understanding Human Cells during Disease’ — ‘LifeTime’From1 Mar 2019 → 30 Apr 2020Funding: Other EU initiatives out of framework
- VIB Grant for Marine Lab_Period:2017-01-01-2021-12-31From1 Jan 2017 → 31 Dec 2021Funding: FRI - Project driven research
Publications
11 - 20 of 78
- An adverse tumor-protective effect of IDO1 inhibition.(2023)
Authors: Joanna Pozniak, Jean-Christophe Marine
Pages: 100941 - The CD58-CD2 axis is co-regulated with PD-L1 via CMTM6 and shapes anti-tumor immunity.(2023)
Authors: Joanna Pozniak, Jean-Christophe Marine
Pages: 1207-1221.e12 - Glucocorticoid activation by HSD11B1 limits T cell-driven interferon signaling and response to PD-1 blockade in melanoma.(2023)
Authors: Joanna Pozniak, Florian Rambow, Jean-Christophe Marine
Pages: e004150 - Pharmacological induction of membrane lipid poly-unsaturation sensitizes melanoma to ROS inducers and overcomes acquired resistance to targeted therapy.(2023)
Authors: Florian Rambow, Ginevra Doglioni, Patrizia Agostinis, Sarah-Maria Fendt, Jean-Christophe Marine
Pages: 92 - A palmitate-rich metastatic niche enables metastasis growth via p65 acetylation resulting in pro-metastatic NF-?B signaling.(2023)
Authors: Patricia Altea Manzano, Ginevra Doglioni, Alejandro Cuadros, Juan Fernandez Garcia, Qi Wu, Xiaozheng Liu, Oskar Marin Bejar, Sofie Demeyer, Margherita Demicco, Hamza Furkan Alkan, et al.
Pages: 344-364 - SERPINB9 is commonly amplified and high expression in cancer cells correlates with poor immune checkpoint blockade response.(2022)
Authors: Joanna Pozniak, Ewout Landeloos, Jean-Christophe Marine
Pages: 2139074 - The long non-coding RNA SAMMSON is essential for uveal melanoma cell survival.(2022)
Authors: Louis Delhaye, Peihua Zhao, Jean-Christophe Marine, Sven Eyckerman
Pages: 15-25 - Mapping the Immune Landscape in Metastatic Melanoma Reveals Localized Cell-Cell Interactions That Predict Immunotherapy Response.(2022)
Authors: Jean-Christophe Marine
Pages: 3275-3290 - PHGDH heterogeneity potentiates cancer cell dissemination and metastasis.(2022)
Authors: Matteo Rossi, Patricia Altea Manzano, Margherita Demicco, Ginevra Doglioni, Anke Vandekeere, Alejandro Cuadros, Juan Fernandez Garcia, Carla Riera Domingo, Hamza Furkan Alkan, Lindsay Broadfield, et al.
Pages: 747-753 - Treatment for giant congenital nevi moves a step closer.(2022)
Authors: Joanna Pozniak, Jean-Christophe Marine
Pages: 799-800
Patents
1 - 9 of 9
- RXR ANTAGONISTS FOR USE IN MELANOMA TREATMENT (Inventor)
- MELANOMA DISEASE STRATIFICATION (Inventor)
- CD36 ANTAGONISTS FOR USE IN MELANOMA TREATMENT (Inventor)
- CD36 ANTAGONISTS FOR USE IN MELANOMA TREATMENT (Inventor)
- MELANOMA DISEASE STRATIFICATION (Inventor)
- RXR ANTAGONISTS FOR USE IN MELANOMA TREATMENT (Inventor)
- CD36 ANTAGONISTS FOR USE IN MELANOMA TREATMENT (Inventor)
- MELANOMA DISEASE STRATIFICATION (Inventor)
- RXR ANTAGONISTS FOR USE IN MELANOMA TREATMENT (Inventor)